Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research Institute, Konyang University College of Medicine, Seoul, South Korea.
Retina. 2018 Nov;38(11):2150-2158. doi: 10.1097/IAE.0000000000001862.
To compare the effectiveness of intravitreal injection of aflibercept with ranibizumab in patients with Type 3 neovascularization.
Sixty-three treatment-naive eyes with Type 3 neovascularization (58 patients) were retrospectively analyzed. The eyes had received intravitreal aflibercept or ranibizumab injections. All patients were treated using an initial series of three monthly loading injections, followed by further injections as required. The visual and anatomical outcomes of treatment were evaluated after 12 months.
The mean best-corrected visual acuity in the aflibercept-treated group (21 eyes), expressed as the logarithm of the minimum angle of resolution, improved from 0.71 ± 0.42 (Snellen equivalent; 20/102) to 0.54 ± 0.39 (20/69) after 12 months of treatment (P = 0.022). Similarly, in the ranibizumab-treated group (42 eyes), the best-corrected visual acuity improved from 0.68 ± 0.38 (20/95) to 0.53 ± 0.36 (20/67) (P = 0.013) at 12 months. The central foveal thickness decreased in the aflibercept-treated group from 356 ± 139 μm to 212 ± 155 μm and in the ranibizumab-treated group from 348 ± 177 μm to 208 ± 161 μm (P = 0.014 and P = 0.017, respectively). There was no significant difference between the groups about improvement in best-corrected visual acuity or decrease in central foveal thickness. However, geographic atrophy was significantly more frequent in the aflibercept-treated group, occurring in 42.9% of eyes, than in the ranibizumab-treated group (19.0% of eyes; P = 0.045).
There was no difference between the aflibercept and ranibizumab treatments in terms of visual acuity improvement after 12 months in patients with Type 3 neovascularization. However, geographic atrophy developed more frequently in the aflibercept-treated group.
比较玻璃体内注射阿柏西普与雷珠单抗治疗 3 型新生血管化的疗效。
回顾性分析 58 例（63 只眼）3 型新生血管化的初治患者。玻璃体内注射阿柏西普或雷珠单抗。所有患者均接受初始连续 3 个月的负荷剂量注射，之后根据需要进行进一步注射。治疗 12 个月后，评估视力和解剖结构的治疗效果。
阿柏西普治疗组（21 只眼）的最佳矫正视力平均对数视力（最小分辨角视力）从治疗前的 0.71±0.42（20/102）提高到 12 个月后的 0.54±0.39（20/69）（P=0.022）。同样，雷珠单抗治疗组（42 只眼）的最佳矫正视力从治疗前的 0.68±0.38（20/95）提高到 12 个月后的 0.53±0.36（20/67）（P=0.013）。阿柏西普治疗组的中央视网膜厚度从 356±139μm 下降到 212±155μm，雷珠单抗治疗组从 348±177μm 下降到 208±161μm（P=0.014 和 P=0.017）。两组之间最佳矫正视力的改善或中央视网膜厚度的降低没有显著差异。然而，在阿柏西普治疗组中，更常见的是地图样萎缩（42.9%的眼），而在雷珠单抗治疗组中，更常见的是地图样萎缩（19.0%的眼）（P=0.045）。
在 3 型新生血管化患者中，治疗 12 个月后，阿柏西普与雷珠单抗治疗在视力改善方面无差异。然而，阿柏西普治疗组更常发生地图样萎缩。
